Anidulafungin: A novel echinocandin for candida infections

Future Microbiology

Volumn 3, Issue 6, 2008, Pages 593-601

  de la Torre, Pola ^a   Meyer, Daniel K ^a   Reboli, Annette C ^a  

^a Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

Author keywords

Anidulafungin; Echinocandin; Invasive candidiasis

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CYTOCHROME P450; DEXAMETHASONE; DNA; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; METRONIDAZOLE; MICAFUNGIN; PHENYTOIN; PLACEBO; RIFAMPICIN; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN;

ABDOMINAL ABSCESS; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; CROSS RESISTANCE; DNA SYNTHESIS INHIBITION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; ESOPHAGUS CANDIDIASIS; EUROPEAN UNION; FEBRILE NEUTROPENIA; FEVER; FUNGICIDAL ACTIVITY; HEPATITIS; HUMAN; HYPOKALEMIA; HYPOTENSION; KIDNEY FAILURE; LIVER FAILURE; LIVER FUNCTION TEST; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; STEADY STATE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; URTICARIA; VOMITING; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL VIABILITY; REVIEW;

ASPERGILLUS; CANDIDA;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; INJECTIONS, INTRAVENOUS; MICROBIAL VIABILITY; UNITED STATES;

EID: 59849113829     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.6.593     Document Type: Article

References (49)

1. McNeil MM, Nash SL, Hajjeh RA et al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Inf. Dis. 33(5), 641-646 (2001).
2. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Rev. Micro. 20(1), 133-163 (2007).
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24.179 cases from a prospective nationwide surveillance study. Clin. Inf. Dis. 39(3), 309-317 (2004).
4. Spellberg BJ, Filler SG, Edwards JE Jr: Current treatment strategies for disseminated candidiasis. Clin. Inf. Dis. 42(2), 244-251 (2006).
5. Arathoon EG: Clinical efficacy of the echinocandin antifungals. Curr Opin Infect Dis. 14(6), 685-691 (2001).
6. Morris MI, Villman M: Echinocandins in the management of invasive fungal infections, part 1. Am. J. Health Syst. Pharm. 63(18), 1693-1703 (2006).
7. Denning DW: Echinocandin antifungal drugs. Lancet 362(9390), 1142-1151 (2003).
8. Arakan S, Rex JH: New agents for the treatment of systemic fungal infections-current status. Expert Opin. Emerg. Drugs 7(1), 3-32 (2002).
9. No authors listed. Anidulafungin: ECHB, LY 303355, V-echinocandin, VEC, VER 002, VER-02. Drugs RD 4(3), 167-173 (2003).
10. Anidulafungin (Eraxis), prescribing information. Pfizer, New York, NY, USA (2007).
11. Anidulafungin (Ecalta), prescribing information. Pfizer, Sandwich, Kent, UK (2008).
12. Turner MS, Drew RH, Perfect JR: Emerging echinocandins for the treatment of invasive fungal infections. Expert Opin. Emerg. Drugs 11(2), 231-250 (2006).
13. Micafungin (Mycamine), prescribing information. Astellas, Deerfield, IL, USA (2008).
14. Caspofungin (Cancidas). European Medicines Agency, London, UK (2001).
15. Micafungin (Mycamine). European Medicines Agency, London, UK (2008).
16. Baddley JW, Moser SA: Emerging fungal resistance. Clin. Lab. Med. 24(3), 721-735 (2004).
17. Eschenauer G, DePestel DD, Carver PL: Comparison of echinocandin antifungals. Ther. Clin. Risk Manag. 3(1), 71-96 (2007).
18. Park S, Kelly J, Nielsen Kahn J et al.: Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49(8), 3264-3273 (2005).
19. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS: Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57(4), 705-708 (2006).
20. Moudgal V, Little T, Boikov D, Vazquez JA: Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49(2), 767-769 (2005).
21. Ketko AK, Sobel JD, Akins RA: Gene overexpression analysis of echinocandin resistance in Candida albicans. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 17-20 September 2006 (M-1758).
22. Kahn JN, Garcia-Effron G, Hsu M-J, Park S, Marr KA, Perlin DS: Acquired echinocandin resistancc in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51(5), 1876-1878 (2007).
23. Ghannoum MA, Chen A, Buhari M, Chandra J, Mukerjee, PK, Vazquez J: Multi-echinocandin resistant Candida parapsilosis: an emerging pathogen. Presented at 45 th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16-19 December 2005 (M-722a).
24. Dowell JA, Pu F, Lee J, Stogniew M, Krause D, Henkel T: A clinical mass balance Study of anidulafungin showing complete fecal elimination. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003 (A-1576).
25. McCormack PL, Perry CM: Caspofungin: a review of its use iwhe treatment ot fungal infections. Adis Drug Evaluation. 65(14), 2049-2068.(2005).
26. Chandraskckar PH, Sobel JD. Micafungin: a new echinocandin. Clin. Inf. Dis. 42(8), 1171-1178 (2006).
27. Stogniew M, Pu F, Henkel T, Dowell J: Anidulafungin biotransformation in humans is by degradation not metabolism. Presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, UK, 10-13 May 2003 (P-1223).
28. Dowell JA, Schranz J, Baruch A, Foster G: Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J. Clin. Pharmacol. 45(12), 1373-1375 (2005).
29. Caspofungin (Cancidas), prescribing information. Merck, Whitehouse Station NJ, USA (2008).
30. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T: Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44, 590-598 (2004).
31. Dowell JA, Stogniew M, Krause D, Henkel T: Anidulafungin pharmacokinetics/pharmacodynamic correlation: treatmem; of esophageal candidiasis. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003 (A-1578).
32. Benjamin DK, Driscoll T, Seibel NL et al.: Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50(2), 632-638 (2006).
33. Gumbo T, Drusano GL. Liu W et al.: Anidulatungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob. Agents and Chemother. 50(11), 3695-3700 (2006).
34. Andes D, Dickema DJ. Pfaller MA et al.: In viro pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52(2), 539-550 (2008).
35. Momson VA: Echinocandin antifungals: review and update. Expert Rev. Anti-Infect. Ther. 4(2), 325-342 (2006).
36. Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64(18), 1997-2020 (2004).
37. Odabasi Z, Paetznick VL, RodrigueZ JR, Chen E, Ostrosky-Zeichner L: In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 48(5), 1912-1915 (2004).
38. Pfaller MA, Dickema DJ, Ostroskv-Zeichner L et al.: Correlation of MIC wich outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46(8), 2620-2629 (2008).
39. Pfaller MA, Dickema DJ, Gibbs DL et al.: Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK antifungal surveillance program, 2001 to 2005. J. Clin. Microbiol. 46(3), 842-849 (2008).
40. Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP: In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-flucytosine against Candida species. Int. J. Antimicrob. Agents 27(2), 174-177 (2006).
41. Krause DS, Simjee AE, van Rensburg C et al.: A randomized, double-blind trial of anildulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39(6), 770-775 (2004).
42. Vazquez JA, Schranz, JA, Clark K et al.: A Phase 2, open-label study of the safety and efficacy of intravenous a nidulafungin as a treatment for azole-refractory mucosal candidiasis. J. Acquire Immune defic. Syndr. 48(3), 304-309 (2008).
43. Krause DS, Reinhardt J, Vazquez JA et al.: Phase 2, randomized, dose-ranging study evaluating the safety and efficay of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48(6), 2021-2024 (2008).
44. Reboli AC, Roustein C, Pappas PG et al.: Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356(24). 2472-2482 (2007).
45. No authors listed. Anidulafungin (Eraxis) for Candida infections. Med. Lett. Drugs 48, 43-44 (2005).
46. Schranz J, Krause D, Henkel: Lack of infusion-related adverse events with anidulafungin. Presented at: 15th Congress of the International Society for Human and Animal Mycology. San Antonio, TX, USA, 25-29 May 2003.
47. Vazquez JA: Anidulafungin: a nev echinocandin with a novel profile. Clin. Ther. 27(6), 657-673 (2005).
48. Brielmaier BD, Casbar E, Kurtzeborn CM, McKinnon PS, Ritchie DJ: Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 28(1), 64-73 (2008).
49. Hurren JR, Davis SL, Vazquez JA: What is the risk of disulfiram-like reaction during anidulafungin and metronidazole administration? Presented at: 47th Interscience Conference of Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007 (K-2158).